申请人:Wakamoto Pharmaceutical Co., Ltd.
公开号:US05356916A1
公开(公告)日:1994-10-18
A 1,2,4-oxadiazole derivative is represented by the following general formula (I): ##STR1## wherein R.sup.1 represents a lower alkyl or cycloalkyl group, a lower alkyl group substituted with a halogen atom, a lower alkylamino group or a phenyl group; R.sup.2 represents a hydrogen atom, a lower dialkylamino group, a cyclic alkylamino group, a cyclic amino group having an oxygen or nitrogen atom in the ring, a phenyl group which may be substituted with a halogen atom, a pyridyl group, an imidazolyl group, an alkylimidazolyl group, a benzimidazolyl group or a 2-oxopyrrolidinyl group; and n is 1, 2 or 3. The derivative has excellent monoamine oxidase-inhibitory activity and is effective as a medicine for treating Parkinson's disease.
一种1,2,4-噁二唑衍生物由以下通用式(I)表示:##STR1##其中R.sup.1代表低烷基或环烷基基团,被卤素原子取代的低烷基基团,低烷基氨基基团或苯基;R.sup.2代表氢原子,低二烷基氨基基团,环烷基氨基基团,环氨基基团在环中具有氧原子或氮原子,可能被卤素原子取代的苯基,吡啶基,咪唑基,烷基咪唑基,苯并咪唑基或2-氧代吡咯烷基;n为1、2或3。该衍生物具有出色的单胺氧化酶抑制活性,并可作为治疗帕金森病的药物。